Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Incidence and Prognostic Impact of Molecular and Genetic Abnormalities in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasms

NCT02084563 is registered in ClinicalTrials.gov with Hospital Israelita Albert Einstein as lead sponsor.

NCT NCT02084563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02084563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Incidence and Prognostic Impact of Molecular and Genetic Abnormalities in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasms
Lead sponsor
Hospital Israelita Albert Einstein
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2012
Completion date
November 30, 2016
Enrollment
455 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms, myeloproliferative/myelodysplastic neoplasm